{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:22:20Z","timestamp":1788355340824,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","transplantation-proceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.transproceed.2018.01.022","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T22:40:00Z","timestamp":1525387200000},"page":"987-992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"S.D.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-M.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.01.022_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.transproceed.2006.01.016","article-title":"Health-related quality of life after kidney transplantation in comparison intermittent hemodialysis, peritoneal dialysis, and normal controls","volume":"38","author":"Ogutmen","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.01.022_bib2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"issue":"Suppl. 3","key":"10.1016\/j.transproceed.2018.01.022_bib3","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.01.022_bib4","unstructured":"National Institutes of Health NIoDaDaKD. RDS U. USRDS 2013 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. 2013."},{"key":"10.1016\/j.transproceed.2018.01.022_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00063030-200519010-00005","article-title":"Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review","volume":"19","author":"Nashan","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.transproceed.2018.01.022_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2217\/imt.11.72","article-title":"Use of monoclonal antibodies in renal transplantation","volume":"3","author":"van den Hoogen","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.transproceed.2018.01.022_bib7","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/S0041-1345(00)01810-8","article-title":"Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results","volume":"32","author":"Martins","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.01.022_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transproceed.2018.01.022_bib9","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1111\/sdi.12342","article-title":"A\u00a0meta-analysis of randomized clinical trials assessing hemodialysis access thrombosis based on access flow monitoring: where do we stand?","volume":"28","author":"Muchayi","year":"2015","journal-title":"Semin Dial"},{"key":"10.1016\/j.transproceed.2018.01.022_bib10","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.transproceed.2018.01.022_bib11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.transproceed.2018.01.022_bib12","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/BRS.0b013e3181b1c99f","article-title":"2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group","volume":"34","author":"Furlan","year":"2009","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.transproceed.2018.01.022_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2013.02.044","article-title":"Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"132","author":"Bae","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.transproceed.2018.01.022_bib14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.transproceed.2018.01.022_bib15","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.transproceed.2018.01.022_bib16","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.transproceed.2018.01.022_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijsu.2017.09.002","article-title":"Interventions for treating 3- or 4-part proximal humeral fractures in elderly patient: a network meta-analysis of randomized controlled trials","volume":"48","author":"Du","year":"2017","journal-title":"Int J Surg"},{"key":"10.1016\/j.transproceed.2018.01.022_bib18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.transproceed.2018.01.022_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.transproceed.2018.01.022_bib20","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.01.022_bib21","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.01.022_bib22","first-page":"664","article-title":"Alemtuzumab induction therapy in highly sensitized kidney transplant recipients","volume":"124","author":"Lu","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.transproceed.2018.01.022_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A\u00a0randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.01.022_bib24","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.transproceed.2010.08.045","article-title":"Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation","volume":"42","author":"Ciancio","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.01.022_bib25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.01.022_bib26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00007890-200112270-00008","article-title":"Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection","volume":"72","author":"Sollinger","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.01.022_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyll\u00f6nen","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.01.022_bib28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.01.022_bib29","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0041-1345(03)00679-1","article-title":"ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results","volume":"35","author":"Tullius","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.01.022_bib30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/tri.12991","article-title":"Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective","volume":"30","author":"Cremaschi","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2018.01.022_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.01.022_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1399-0012.2007.00742.x","article-title":"A\u00a0randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation","volume":"22","author":"Farney","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.01.022_bib33","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfm873","article-title":"CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A","volume":"23","author":"Abou-Ayache","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.01.022_bib34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","article-title":"Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation","volume":"80","author":"Vathsala","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.01.022_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.transproceed.2004.12.079","article-title":"Limited-dose daclizumab versus basiliximab: a comparison of cost and efficacy in preventing acute rejection","volume":"37","author":"Pham","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.01.022_bib36","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.01.022_bib37","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.TP.0000441089.39840.66","article-title":"Randomized trial of three induction antibodies in kidney transplantation: long-term results","volume":"97","author":"Ciancio","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.01.022_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11255-007-9242-6","article-title":"Long-term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation","volume":"40","author":"Sheashaa","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.transproceed.2018.01.022_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.trim.2014.09.011","article-title":"Anti-B cell therapy with rituximab as induction therapy in renal transplantation","volume":"31","author":"Joosten","year":"2014","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2018.01.022_bib40","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/TP.0b013e3181a235fd","article-title":"A\u00a0randomized, double blind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation","volume":"87","author":"Tyden","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.01.022_bib41","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0041-1345(02)03048-8","article-title":"A\u00a0three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients","volume":"34","author":"Charpentier","year":"2002","journal-title":"Transplant Proc"},{"issue":"Suppl. 1","key":"10.1016\/j.transproceed.2018.01.022_bib42","first-page":"S293","article-title":"Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation\u2014a prospective, randomized study","volume":"13","author":"Yussim","year":"2000","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2018.01.022_bib43","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial","volume":"384","author":"Haynes","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2018.01.022_bib44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/TP.0b013e31822ca7ca","article-title":"Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy\u2014an open label, randomized trial","volume":"92","author":"Chan","year":"2011","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.transproceed.2018.01.022_bib45","first-page":"CD003897","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","author":"Webster","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transproceed.2018.01.022_bib46","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1093\/ndt\/14.12.2824","article-title":"Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation","volume":"14","author":"Maes","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.01.022_bib47","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.transproceed.2010.02.088","article-title":"Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis","volume":"42","author":"Liu","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.01.022_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clim.2011.10.008","article-title":"Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis","volume":"142","author":"Martin","year":"2012","journal-title":"Clin Immunol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518300666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518300666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T10:09:06Z","timestamp":1720260546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134518300666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0041134518300666"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.01.022","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}